Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. Market Capitalization on January 14, 2025: USD 240.99 M

Benitec Biopharma Inc. Market Capitalization is USD 240.99 M on January 14, 2025, a 1,345.30% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Benitec Biopharma Inc. 52-week high Market Capitalization is USD 308.79 M on December 31, 2024, which is 28.14% above the current Market Capitalization.
Benitec Biopharma Inc. 52-week low Market Capitalization is USD 15.93 M on February 14, 2024, which is -93.39% below the current Market Capitalization.
Benitec Biopharma Inc. average Market Capitalization for the last 52 weeks is USD 146.60 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years